Cargando…

Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

Detalles Bibliográficos
Autores principales:	Weidenbacher, Payton A.-B., Sanyal, Mrinmoy, Friedland, Natalia, Tang, Shaogeng, Arunachalam, Prabhu S., Hu, Mengyun, Kumru, Ozan S., Morris, Mary Kate, Fontenot, Jane, Shirreff, Lisa, Do, Jonathan, Cheng, Ya-Chen, Vasudevan, Gayathri, Feinberg, Mark B., Villinger, Francois J., Hanson, Carl, Joshi, Sangeeta B., Volkin, David B., Pulendran, Bali, Kim, Peter S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556009/ https://www.ncbi.nlm.nih.gov/pubmed/37798288 http://dx.doi.org/10.1038/s41467-023-42061-4

Ejemplares similares

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
por: Weidenbacher, Payton A.-B., et al.
Publicado: (2022)

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
por: Weidenbacher, Payton A.-B., et al.
Publicado: (2023)

Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines
por: Kumru, Ozan S., et al.
Publicado: (2023)

Designing epitope-focused vaccines via antigen reorientation
por: Xu, Duo, et al.
Publicado: (2022)

Simplified Purification of Glycoprotein-Modified Ferritin Nanoparticles for Vaccine Development
por: Weidenbacher, Payton, et al.
Publicado: (2022)

A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice
por: Powell, Abigail E., et al.
Publicado: (2020)

A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice
por: Powell, Abigail E., et al.
Publicado: (2021)

Decreased efficacy of a COVID-19 vaccine due to mutations present in early SARS-CoV-2 variants of concern
por: Weidenbacher, Payton A.-B., et al.
Publicado: (2023)

Chemically Modified Bacterial Sacculi as a Vaccine Microparticle Scaffold
por: Weidenbacher, Payton A.-B., et al.
Publicado: (2022)

Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate
por: Kumar, Prashant, et al.
Publicado: (2023)

Preformulation Characterization and Stability Assessments of Secretory IgA Monoclonal Antibodies as Potential Candidates for Passive Immunization by Oral Administration
por: Hu, Yue, et al.
Publicado: (2020)

Antisera by the Mouth
por: Basu, K. M.
Publicado: (1932)

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
por: Li, Chunfeng, et al.
Publicado: (2022)

The Use of the Domestic Fowl for the Preparation of Diagnostic Antisera
por: Pasricha, C. L., et al.
Publicado: (1939)

Emerging concepts in the science of vaccine adjuvants
por: Pulendran, Bali, et al.
Publicado: (2021)

Effect of Formulation Variables on the Stability of a Live, Rotavirus (RV3-BB) Vaccine Candidate using in vitro Gastric Digestion Models to Mimic Oral Delivery
por: Kumar, Prashant, et al.
Publicado: (2021)

THE THERAPEUTIC VALUE OF INTRAMUSCULAR DOSAGE OF TYPE I PNEUMOCOCCUS ANTISERA
por: Curphey, Theodore J., et al.
Publicado: (1932)

ANTINUCLEAR ANTIBODIES IN RABBIT ANTISERA
por: Barnett, Eugene V., et al.
Publicado: (1966)

Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine
por: Kumru, Ozan S., et al.
Publicado: (2019)

Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries
por: Kumar, Prashant, et al.
Publicado: (2021)

Human sperm TMEM95 binds eggs and facilitates membrane fusion
por: Tang, Shaogeng, et al.
Publicado: (2022)

Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018(TM) Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 RBD Antigen
por: Bajoria, Sakshi, et al.
Publicado: (2023)

Protect, modify, deprotect (PMD): A strategy for creating vaccines to elicit antibodies targeting a specific epitope
por: Weidenbacher, Payton A., et al.
Publicado: (2019)

QUANTITATIVE STUDIES OF BRUCELLA PRECIPITIN SYSTEMS : I. PRECIPITATION OF HOMOLOGOUS ANTISERA BY BRUCELLA ENDOANTIGENS
por: Pennell, R. B., et al.
Publicado: (1938)

QUANTITATIVE STUDIES OF BRUCELLA PRECIPITIN SYSTEMS : II. THE PRECIPITATION OF HETEROLOGOUS ANTISERA BY BRUCELLA ENDOANTIGENS
por: Pennell, R. B., et al.
Publicado: (1938)

ANTISERA, TOXOIDS, VACCINES AND TUBERCULINS IN PROPHYLAXIS AND TREATMENT
Publicado: (1955)

ANTISERA, TOXOIDS, VACCINES AND TUBERCULIN IN PROPHYLAXIS AND TREATMENT
Publicado: (1958)

ANTISERA, TOXOIDS, VACCINES AND TUBERCULINS IN PROPHYLAXIS AND TREATMENT
Publicado: (1961)

ANTISERA, TOXOIDS, VACCINES AND TUBERCULINS IN PROPHYLAXIS AND TREATMENT
Publicado: (1962)

THE INHIBITION OF STREPTOCOCCAL DESOXYRIBONUCLEASE BY RABBIT AND HUMAN ANTISERA
por: McCarty, Maclyn
Publicado: (1949)

MACROGLOBULINEMIA : II. ANTISERA SPECIFIC FOR PATHOLOGICAL MACROGLOBULINS
por: Korngold, Leonhard, et al.
Publicado: (1957)

STUDIES ON HEMAGGLUTINATION AND HEMOLYSIS BY ESCHERICHIA COLI ANTISERA
por: Neter, Erwin, et al.
Publicado: (1952)

Inhibition of T-antigen-binding cells by idiotypic antisera
Publicado: (1977)

Generation of therapeutic antisera for emerging viral infections
por: Schmidt, Rebecca, et al.
Publicado: (2018)

A COMPARISON OF HUMAN ANTISERA TO PURIFIED DIPHTHERIA TOXOID WITH ANTISERA TO OTHER PURIFIED ANTIGENS BY QUANTITATIVE PRECIPITIN AND GEL DIFFUSION TECHNIQUES
por: Finger, Irving, et al.
Publicado: (1958)

Investigation of a monoclonal antibody against enterotoxigenic Escherichia coli, expressed as secretory IgA1 and IgA2 in plants
por: Teh, Audrey Y-H, et al.
Publicado: (2021)

STUDIES ON RABBIT LYMPHOCYTES IN VITRO : II. INDUCTION OF BLAST TRANSFORMATION WITH ANTISERA TO SIX IGG ALLOTYPES AND SUMMATION WITH MIXTURES OF ANTISERA TO DIFFERENT ALLOTYPES
por: Gell, P. G. H., et al.
Publicado: (1965)

LYMPHOCYTE-MEDIATED CYTOTOXICITY IN VITRO : EFFECT OF ENHANCING ANTISERA
por: Klein, William J.
Publicado: (1971)

STUDIES OF IDIOTYPIC ANTIBODIES : PRODUCTION AND CHARACTERIZATION OF AUTOANTIIDIOTYPIC ANTISERA
por: Rodkey, L. Scott
Publicado: (1974)

OBSERVATIONS ON THE AGGLUTINATION OF POLYSACCHARIDE-TREATED ERYTHROCYTES BY TULAREMIA ANTISERA
por: Alexander, Mary M., et al.
Publicado: (1950)

Cannot write session to /tmp/vufind_sessions/sess_ppufmh3a6hr65bq5f50ecrm6st